Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2004 08:15 ET | Source: Xenova Group PLC

Xenova Group PLC Programme Update

SLOUGH, U.K., Nov. 16, 2004 (PRIMEZONE) -- Xenova Group plc (Nadaq:XNVA) (LSE:XEN) today announced that Millennium Pharmaceuticals Inc. (Nasdaq:MLNM) (Millennium), Xenova's North American partner for...
November 04, 2004 02:43 ET | Source: Xenova Group PLC

Xenova Group PLC -- Third Quarter Results, 2004

SLOUGH, U.K., Nov. 4, 2004 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced its results for the quarter ended 30 September 2004. Quarterly Highlights -- TransMID(tm) -...
September 03, 2004 04:23 ET | Source: Xenova Group PLC

Xenova Group PLC: Canadian Manufacturing Facility Sale Completes Planned Disposals

SLOUGH, U.K., Sept. 3, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announces that it has completed the disposal of its manufacturing facility in Edmonton, Canada, to QSV Biologics...
August 31, 2004 10:53 ET | Source: Xenova Group PLC

Xenova Group plc

SLOUGH, U.K., Aug. 31, 2004 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) announces that it is in late stage discussions concerning the disposal of its manufacturing facility in Edmonton,...
August 11, 2004 02:24 ET | Source: Xenova Group PLC

Xenova Group PLC -- Interim Results for the First Half of 2004

SLOUGH, UK, Aug. 11, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today its results for the six months ended 30 June 2004. Year to Date Highlights Development --...
July 14, 2004 03:59 ET | Source: Xenova Group PLC

Successful Results from Second Clinical Trial of Anti-Smoking Vaccine, TA-NIC

SLOUGH, U.K., July 14, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today initial results from the second clinical trial of TA-NIC, the Company's therapeutic vaccine being...
July 07, 2004 02:28 ET | Source: Xenova Group PLC

TransMID -- First Patient Treated in Pivotal Phase III GBM Trial

SLOUGH, U.K., July 7, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today that patient dosing has begun in the Phase III clinical trial of TransMID(TM) for the treatment of...
June 24, 2004 02:11 ET | Source: Xenova Group PLC

Xenova to Host R&D Days

SLOUGH, U.K., June 24, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) will next week host an Investor/Analyst R&D Day in both New York and London. The event in New York will be held...
June 21, 2004 02:18 ET | Source: Xenova Group PLC

Xenova Receives Manufacturer's Authorisation from MHRA

SLOUGH, U.K., June 21, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today that it has received a Manufacturer's Authorisation -- Investigational Medicinal Products from the...
June 14, 2004 02:35 ET | Source: Xenova Group PLC

Xenova Group plc -- Positive Results from TA-CD Cocaine Vaccine Trial

SLOUGH, U.K., June 14, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today the presentation of results of two dose escalation Phase II studies of TA-CD, a vaccine being...